May 24, 2011 - HBV/HIV Coinfected Iranian Patients Under Lamivudine Treatment ... Iranian patients undergoing long-term lamivudine therapy from the clinical ...
Current HIV Research, 2011, 9, 263-269
263
Detection of Hepatitis B Virus Variants in HBV Monoinfected and HBV/HIV Coinfected Iranian Patients Under Lamivudine Treatment Mohammad Reza Aghasadeghi*,1, Golnaz Bahramali1, Seyed Mehdi Sadat1, Ahmad Farahani Far1,2, Minoo Mohraz3, Seyed Davar Siadat1, Ehsan Mostafavi4, Arash Memarnejadian1, Mehdi Shafiee Ardestani1, Rouhollah Vahabpour1, Alireza Azizi Saraji1,5 and Seyed Ali Delbaz1 1
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran; 2Islamic Azad University, Karaj Branch, Karaj, Iran; 3Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Science, Tehran, Iran; 4 Department of Epidemiology, Pasteur Institute of Iran, Tehran, Iran; 5Department of Veterinary Laboratory of Sciences, Scientific Society of Veterinary Science, Science and Research Branch, Islamic Azad University, Tehran, Iran Abstract: Chronic hepatitis B affects nearly 10% of HIV-infected patients. Hepatitis B virus (HBV) infection is a dynamic disease and coinfection with HIV impacts directly on the outcome of HBV infection, considerably complicating its natural history, diagnosis, and management. The aim of this study was to compare two cohorts of HBV monoinfected and HBV/HIV coinfected Iranian patients undergoing long-term lamivudine therapy from the clinical and virological aspects, as well as the frequency of detected mutations in HBV genome. To this end, HBV Pol/S regions from 72 patients were PCR-amplified and directly sequenced. Phylogenetic analysis indicated a 40-times higher risk of coinfection with ayw3 subtype of HBV genotype D rather than ayw2 subtype [P40 IU/L)(%)
25(59.3)
16(53.3)
N.Sa
Median LAM-exposure (Months)(SE)
12±3.64
23±2.54
N.Sb
Characteristic Gender (%) (Male/Female) Mean age (Years±SD)
D
D
-
Subtype (%)
15(35.7)
27(90)
